Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001566044-21-000018
Filing Date
2021-04-20
Accepted
2021-04-20 16:47:57
Documents
16
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A vyne-20201231.htm   iXBRL 10-K/A 509266
2 EX-31.1 vyne-20201231x10kaexx311.htm EX-31.1 10850
3 EX-31.2 vyne-20201231x10kaexx312.htm EX-31.2 10838
  Complete submission text file 0001566044-21-000018.txt   797326

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vyne-20201231.xsd EX-101.SCH 2435
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vyne-20201231_cal.xml EX-101.CAL 718
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vyne-20201231_def.xml EX-101.DEF 1651
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vyne-20201231_lab.xml EX-101.LAB 37140
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vyne-20201231_pre.xml EX-101.PRE 19720
9 EXTRACTED XBRL INSTANCE DOCUMENT vyne-20201231_htm.xml XML 17309
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38356 | Film No.: 21838497
SIC: 2834 Pharmaceutical Preparations